This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza virus | 4684 |
influenza viruses | 2013 |
avian influenza | 1923 |
pandemic influenza | 1751 |
influenza vaccine | 1536 |
seasonal influenza | 1263 |
virus infection | 1182 |
influenza vaccination | 1019 |
public health | 963 |
influenza infection | 949 |
influenza pandemic | 832 |
respiratory tract | 791 |
influenza vaccines | 739 |
united states | 721 |
hong kong | 719 |
acute respiratory | 697 |
human influenza | 576 |
immune response | 566 |
highly pathogenic | 485 |
respiratory viruses | 479 |
respiratory syncytial | 478 |
syncytial virus | 450 |
influenza season | 444 |
immune responses | 428 |
health care | 374 |
amino acid | 359 |
virus infections | 358 |
infectious diseases | 358 |
world health | 340 |
severe influenza | 338 |
virus replication | 331 |
influenza surveillance | 325 |
like illness | 322 |
health organization | 307 |
cord uid | 303 |
doc id | 303 |
lower respiratory | 302 |
epithelial cells | 290 |
risk factors | 289 |
pregnant women | 289 |
severe acute | 288 |
vaccine effectiveness | 288 |
pathogenic avian | 288 |
neuraminidase inhibitors | 275 |
respiratory syndrome | 268 |
age groups | 265 |
viral infections | 265 |
systematic review | 261 |
sialic acid | 254 |
clinical trials | 248 |
young children | 243 |
respiratory infections | 242 |
years old | 240 |
respiratory illness | 240 |
swine influenza | 239 |
vaccination coverage | 234 |
live attenuated | 234 |
infected cells | 233 |
viral replication | 229 |
inactivated influenza | 229 |
respiratory virus | 227 |
confirmed influenza | 226 |
disease control | 222 |
upper respiratory | 217 |
cell culture | 216 |
severe disease | 216 |
influenza infections | 213 |
high risk | 211 |
infectious disease | 210 |
influenza activity | 207 |
immune system | 206 |
antiviral treatment | 205 |
antibody responses | 205 |
virus vaccine | 203 |
viral infection | 202 |
antibody response | 199 |
age group | 198 |
universal influenza | 197 |
surveillance system | 197 |
pandemic virus | 196 |
influenza strains | 193 |
antigenic drift | 193 |
viral load | 192 |
novel influenza | 192 |
reverse genetics | 191 |
viral rna | 190 |
hospitalized patients | 189 |
influenza epidemics | 188 |
receptor binding | 188 |
cell responses | 187 |
virus vaccines | 187 |
intensive care | 186 |
antiviral drugs | 184 |
viruses isolated | 183 |
neutralizing antibodies | 182 |
virus strains | 181 |
healthcare workers | 180 |
virus hemagglutinin | 178 |
human infection | 176 |
host cell | 176 |
respiratory disease | 175 |
innate immune | 175 |
type i | 174 |
increased risk | 171 |
infection control | 168 |
gene expression | 167 |
human population | 167 |
may also | 166 |
respiratory distress | 162 |
human transmission | 161 |
animal models | 161 |
respiratory infection | 160 |
healthy adults | 155 |
influenza pandemics | 154 |
iav infection | 154 |
ill patients | 153 |
influenza cases | 153 |
statistically significant | 151 |
attenuated influenza | 150 |
secondary bacterial | 150 |
neuraminidase inhibitor | 150 |
sore throat | 149 |
critically ill | 148 |
chain reaction | 147 |
bacterial pneumonia | 146 |
phylogenetic analysis | 146 |
polymerase chain | 144 |
care workers | 144 |
respiratory symptoms | 144 |
primary care | 141 |
influenza outbreaks | 140 |
pandemic preparedness | 140 |
controlled trial | 138 |
influenza seasons | 137 |
viral shedding | 137 |
clinical features | 137 |
control measures | 137 |
respiratory failure | 135 |
symptom onset | 133 |
distress syndrome | 133 |
tract infections | 131 |
vaccine production | 131 |
influenza pneumonia | 131 |
binding site | 131 |
amino acids | 130 |
human infections | 130 |
respiratory viral | 129 |
human metapneumovirus | 128 |
pdm virus | 127 |
severe pneumonia | 127 |
mdck cells | 127 |
human cases | 127 |
risk groups | 126 |
vaccine development | 126 |
influenza transmission | 126 |
severe illness | 125 |
children aged | 125 |
immunocompromised patients | 124 |
antiviral activity | 123 |
ns protein | 122 |
antiviral therapy | 122 |
young adults | 120 |
acquired pneumonia | 119 |
cleavage site | 119 |
swine flu | 118 |
receptor specificity | 117 |
among children | 117 |
host range | 116 |
social distancing | 116 |
surveillance data | 115 |
older adults | 115 |
infected patients | 114 |
parainfluenza virus | 114 |
protective immunity | 114 |
aged years | 113 |
advisory committee | 113 |
disease severity | 112 |
origin influenza | 112 |
pandemic potential | 111 |
viral pneumonia | 110 |
infected mice | 110 |
general population | 110 |
vaccine strain | 110 |
study period | 108 |
hemorrhagic fever | 108 |
nucleic acid | 108 |
new influenza | 107 |
mortality rate | 107 |
severe cases | 106 |
annual influenza | 106 |
disease burden | 106 |
pandemic strain | 105 |
cell death | 105 |
dendritic cells | 105 |
membrane fusion | 104 |
influenza patients | 103 |
cohort study | 103 |
reverse transcription | 103 |
least one | 103 |
global influenza | 103 |
significantly higher | 102 |
mouse model | 102 |
influenza type | 102 |
lung injury | 101 |
influenza epidemic | 101 |
wild birds | 101 |
previous studies | 100 |
streptococcus pneumoniae | 100 |
otitis media | 100 |
clinical trial | 100 |
case definition | 99 |
sentinel surveillance | 99 |
viral proteins | 98 |
rna viruses | 98 |
factors associated | 98 |
cell lines | 98 |
side effects | 98 |
important role | 97 |
circulating influenza | 97 |
pulmonary disease | 97 |
mortality rates | 97 |
care unit | 97 |
resistant influenza | 97 |
inactivated vaccine | 97 |
confirmed cases | 97 |
human respiratory | 96 |
virus type | 96 |
vaccine virus | 95 |
antigenic shift | 95 |
influenza viral | 95 |
immunization practices | 94 |
adverse events | 94 |
influenza hemagglutinin | 94 |
respiratory pathogens | 94 |
mechanical ventilation | 94 |
cell response | 94 |
staphylococcus aureus | 93 |
logistic regression | 93 |
medical conditions | 93 |
virus influenza | 93 |
antiviral agents | 92 |
previously described | 92 |
hospital admission | 92 |
host factors | 92 |
recent years | 92 |
virus isolation | 92 |
national influenza | 92 |
specific cd | 91 |
among patients | 91 |
present study | 91 |
performed using | 91 |
time rt | 90 |
spanish flu | 89 |
vaccine candidates | 89 |
bacterial infection | 89 |
nuclear export | 89 |
virus isolates | 89 |
inflammatory response | 88 |
diagnostic tests | 88 |
national institute | 88 |
vaccine efficacy | 88 |
time pcr | 88 |
general public | 88 |
lung disease | 88 |
vaccination status | 88 |
oseltamivir resistance | 88 |
like receptor | 87 |
antibody titers | 87 |
spanish influenza | 86 |
monoclonal antibodies | 86 |
weight loss | 86 |
clinical signs | 86 |
first wave | 85 |
randomized controlled | 85 |
incubation period | 85 |
viral respiratory | 85 |
host immune | 84 |
viral genome | 84 |
within days | 84 |
matrix protein | 84 |
fatal cases | 83 |
influenza disease | 83 |
borne encephalitis | 83 |
drug resistance | 83 |
west nile | 83 |
virus ns | 82 |
closely related | 82 |
pandemic vaccine | 82 |
influenza mortality | 82 |
gene segments | 82 |
ion channel | 82 |
median age | 82 |
higher risk | 82 |
ha protein | 81 |
oseltamivir treatment | 81 |
avian viruses | 81 |
human beings | 81 |
middle east | 81 |
chronic obstructive | 81 |
risk factor | 80 |
influenza outbreak | 80 |
northern hemisphere | 80 |
virus transmission | 80 |
severe respiratory | 80 |
within hours | 79 |
southern hemisphere | 79 |
tract infection | 79 |
adult patients | 78 |
high mortality | 78 |
rsv infection | 78 |
bacterial infections | 78 |
high levels | 78 |
real time | 78 |
adaptive immune | 78 |
host response | 77 |
specific antibodies | 77 |
following influenza | 77 |
total number | 77 |
per year | 77 |
next pandemic | 76 |
viral culture | 76 |
parainfluenza viruses | 76 |
rna polymerase | 76 |
serum antibody | 76 |
human airway | 76 |
control group | 76 |
virus titers | 76 |
ha gene | 76 |
obstructive pulmonary | 76 |
clinical management | 76 |
human disease | 75 |
excess mortality | 75 |
cytokine storm | 75 |
surveillance systems | 75 |
rapid antigen | 75 |
influenza illness | 74 |
patients hospitalized | 74 |
cell surface | 74 |
phase i | 74 |
like symptoms | 74 |
icu admission | 74 |
risk perception | 74 |
among influenza | 73 |
host cells | 73 |
wide range | 73 |
authors declare | 73 |
lung tissue | 73 |
north america | 73 |
circulating strains | 73 |
significant differences | 73 |
elderly people | 73 |
viral loads | 73 |
chronic diseases | 73 |
insect cells | 73 |
critical care | 73 |
severely ill | 72 |
cell line | 72 |
virus shedding | 72 |
observational studies | 72 |
southeast asia | 72 |
cellular immune | 72 |
influenza strain | 72 |
vaccination rates | 71 |
control study | 71 |
patients infected | 70 |
acute lung | 70 |
case fatality | 70 |
sample size | 70 |
recent study | 70 |
virus isolated | 70 |
monoclonal antibody | 70 |
immune cells | 70 |
influenza immunization | 70 |
rapid influenza | 70 |
samples collected | 69 |
natural foci | 69 |
virus entry | 69 |
vaccine uptake | 69 |
inflammatory cytokines | 69 |
even though | 68 |
mg kg | 68 |
stranded rna | 68 |
inactivated vaccines | 68 |
vaccine coverage | 68 |
infected individuals | 68 |
neutralizing antibody | 68 |
plasma membrane | 68 |
fatality rate | 68 |
one study | 68 |
nai treatment | 67 |
syndrome coronavirus | 67 |
virus circulation | 67 |
informed consent | 67 |
time series | 67 |
encephalitis virus | 67 |
th century | 67 |
chicken eggs | 67 |
risk group | 67 |
different influenza | 67 |
tissue culture | 66 |
well tolerated | 66 |
confidence interval | 66 |
clinical samples | 66 |
may lead | 65 |
sequence data | 65 |
throat swabs | 65 |
virus subtypes | 65 |
ns gene | 65 |
antiviral drug | 65 |
genetic reassortment | 65 |
mice infected | 65 |
based vaccines | 65 |
clinical characteristics | 65 |
virus strain | 64 |
vaccine strains | 64 |
attack rate | 64 |
hospital admissions | 64 |
respiratory diseases | 64 |
viral titers | 64 |
new zealand | 64 |
virus challenge | 64 |
infection rate | 63 |
virus neuraminidase | 63 |
air pollution | 63 |
inosine pranobex | 63 |
pdm infection | 63 |
mortality associated | 63 |
randomised controlled | 63 |
emergency department | 63 |
relative humidity | 63 |
common cold | 63 |
virus detection | 63 |
air travel | 63 |
two doses | 63 |
epidemic influenza | 62 |
hemagglutination inhibition | 62 |
pandemic risk | 62 |
strains isolated | 62 |
recent studies | 62 |
healthy children | 62 |
antiviral resistance | 61 |
like viruses | 61 |
virus particles | 61 |
nile virus | 61 |
iav infections | 61 |
binding specificity | 61 |
transplant recipients | 61 |
positive samples | 61 |
viruses circulating | 61 |
heart disease | 60 |
sequence analysis | 60 |
confidence intervals | 60 |
controlled trials | 60 |
large number | 60 |
vaccine viruses | 60 |
copyright holder | 60 |
vaccine candidate | 60 |
tested positive | 60 |
significant difference | 60 |
another study | 60 |
million people | 60 |
ili cases | 60 |
developing countries | 59 |
influenza among | 59 |
patients admitted | 59 |
twice daily | 59 |
days post | 59 |
next influenza | 59 |
aquatic birds | 59 |
acute influenza | 59 |
innate immunity | 59 |
myocardial infarction | 59 |
pandemic strains | 59 |
viral titer | 58 |
risk patients | 58 |
southern china | 58 |
peer review | 58 |
stem cell | 58 |
single dose | 58 |
united kingdom | 58 |
new york | 58 |
surface glycoproteins | 58 |
nasal swabs | 57 |
protein kinase | 57 |
risk assessment | 57 |
clinical symptoms | 57 |
virus activity | 57 |
viral clearance | 57 |
nitric oxide | 57 |
infectious virus | 57 |
avian flu | 57 |
respiratory samples | 57 |
secondary site | 57 |
several studies | 57 |
oxidative stress | 57 |
chronic lung | 57 |
also found | 57 |
vaccination among | 56 |
virus genome | 56 |
working group | 56 |
influenza may | 56 |
acid residues | 56 |
close contact | 56 |
granted medrxiv | 56 |
every year | 56 |
clinical data | 56 |
reverse transcriptase | 56 |
flu pandemic | 56 |
author funder | 56 |
including influenza | 56 |
viral ha | 55 |
rapid detection | 55 |
uncomplicated influenza | 55 |
general practitioners | 55 |
mediated immunity | 55 |
may provide | 55 |
cell immunity | 55 |
widely used | 55 |
clinical course | 54 |
study showed | 54 |
laboratory testing | 54 |
statistical significance | 54 |
protective efficacy | 54 |
preventing influenza | 54 |
diabetes mellitus | 54 |
data collection | 54 |
clinical studies | 54 |
necrosis factor | 54 |
body weight | 54 |
general practice | 54 |
mycoplasma pneumoniae | 54 |
pcr assay | 54 |
less likely | 53 |
recombinant influenza | 53 |
odds ratio | 53 |
ili surveillance | 53 |
northern eurasia | 53 |
acid changes | 53 |
hospitalized children | 53 |
rapid diagnosis | 53 |
genetic characterization | 53 |
south korea | 53 |
fever virus | 53 |
trivalent influenza | 53 |
acid substitutions | 53 |
chronic disease | 53 |
nervous system | 53 |
among adults | 53 |
antigenic sites | 53 |
among poultry | 53 |
may occur | 53 |
rights reserved | 52 |
type ii | 52 |
potential pandemic | 52 |
novel swine | 52 |
cell cultures | 52 |
currently available | 52 |
health centers | 52 |
virus subtype | 52 |
human populations | 52 |
proinflammatory cytokines | 52 |
clinical practice | 52 |
east respiratory | 52 |
new pandemic | 51 |
related complications | 51 |
congo hemorrhagic | 51 |
bird flu | 51 |
mass gatherings | 51 |
time reverse | 51 |
placebo group | 51 |
circulating viruses | 51 |
primary influenza | 51 |
vaccinia virus | 51 |
influenza diagnosis | 51 |
van een | 51 |
embryonated chicken | 51 |
dna vaccines | 50 |
health emergency | 50 |
fusion peptide | 50 |
health authorities | 50 |
specific antibody | 50 |
cardiovascular disease | 50 |
ili patients | 50 |
influenza neuraminidase | 50 |
current study | 50 |
competing interests | 50 |
type virus | 50 |
far east | 50 |
peripheral blood | 50 |
sentinel sites | 50 |
natural infection | 50 |
tumor necrosis | 50 |
pandemic planning | 50 |
alveolar macrophages | 50 |
human lung | 50 |
future studies | 50 |
pediatric patients | 49 |
sialic acids | 49 |
prospective study | 49 |
mammalian cells | 49 |
absolute humidity | 49 |
highly conserved | 49 |
dna vaccine | 49 |
high level | 49 |
viral envelope | 49 |
antigen tests | 49 |
emerging infectious | 49 |
infectious agents | 49 |
binding sites | 49 |
broadly neutralizing | 49 |
transcription polymerase | 49 |
illness onset | 49 |
st century | 48 |
different subtypes | 48 |
pcr assays | 48 |
airway epithelium | 48 |
adults aged | 48 |
internal genes | 48 |
pathogenic influenza | 48 |
underlying medical | 48 |
new virus | 48 |
significantly lower | 48 |
version posted | 48 |
taken together | 48 |
respiratory specimens | 48 |
many countries | 48 |
viral polymerase | 48 |
currently circulating | 48 |
ferret model | 48 |
elderly patients | 48 |
van het | 48 |
study design | 48 |
pandemic viruses | 48 |
infection among | 47 |
results suggest | 47 |
humoral immune | 47 |
adjuvanted vaccine | 47 |
following infection | 47 |
disease surveillance | 47 |
universal vaccine | 47 |
resistant viruses | 47 |
hand hygiene | 47 |
influenza incidence | 47 |
may result | 47 |
virus proteins | 47 |
infect dis | 47 |
heart failure | 47 |
influenza research | 47 |
seven days | 46 |
study population | 46 |
two days | 46 |
animal model | 46 |
care facilities | 46 |
commercially available | 46 |
significantly reduced | 46 |
viruses may | 46 |
reuse allowed | 46 |
age distribution | 46 |
like particles | 46 |
clinical outcomes | 46 |
different age | 46 |
based vaccine | 46 |
oral oseltamivir | 46 |
virus may | 46 |
pneumococcal vaccination | 46 |
vaccination rate | 46 |
early stages | 46 |
existing immunity | 46 |
viral entry | 46 |
canine kidney | 46 |
respir viruses | 46 |
i ifn | 46 |
virus selection | 46 |
without permission | 46 |
suspected influenza | 46 |
nasopharyngeal swabs | 46 |
clinical specimens | 46 |
allowed without | 46 |
adverse effects | 46 |
household transmission | 46 |
flu vaccine | 46 |
severe pandemic | 46 |
infection may | 46 |
iav replication | 46 |
family members | 46 |
human viruses | 45 |
influenza seasonality | 45 |
health service | 45 |
case series | 45 |
medical care | 45 |
adults hospitalized | 45 |
health center | 45 |
resistant virus | 45 |
influenza subtypes | 45 |
elderly persons | 45 |
study conducted | 45 |
bacterial pathogens | 45 |
serum samples | 45 |
two different | 45 |
table shows | 45 |
symptoms onset | 45 |
related pneumonia | 45 |
virus types | 45 |
pandemic threat | 45 |
pb gene | 45 |
influenza prevention | 45 |
memory cd | 45 |
direct contact | 44 |
medical research | 44 |
aerosol transmission | 44 |
based influenza | 44 |
infect humans | 44 |
wild type | 44 |
see table | 44 |
clinical presentation | 44 |
ae log | 44 |
children years | 44 |
ha cleavage | 44 |
respiratory illnesses | 44 |
times higher | 44 |
emergency management | 44 |
maximum likelihood | 44 |
bone marrow | 44 |
migratory birds | 44 |
central nervous | 44 |
embryonated eggs | 44 |
maternal influenza | 44 |
cytokine responses | 44 |
human cells | 44 |
reproduction number | 44 |
human macrophages | 44 |
surveillance network | 44 |
severe outcomes | 44 |
early detection | 43 |
primary site | 43 |
kong influenza | 43 |
income countries | 43 |
data suggest | 43 |
study influenza | 43 |
adjuvanted influenza | 43 |
life cycle | 43 |
regression model | 43 |
attack rates | 43 |
patients without | 43 |
herpes simplex | 43 |
mortality among | 43 |
influenza preparedness | 43 |
associated encephalopathy | 42 |
preventive measures | 42 |
pandemic response | 42 |
requiring hospitalization | 42 |
emerging influenza | 42 |
subunit vaccines | 42 |
european countries | 42 |
vaccine safety | 42 |
rural areas | 42 |
human monoclonal | 42 |
study group | 42 |
human health | 42 |
respiratory epithelial | 42 |
na gene | 42 |
health officials | 42 |
primary viral | 42 |
also observed | 42 |
case report | 42 |
candidate vaccine | 42 |
respiratory epithelium | 42 |
whole virus | 42 |
predictive value | 42 |
lung epithelial | 42 |
may help | 42 |
two groups | 42 |
globular head | 42 |
domestic poultry | 42 |
death certificates | 41 |
risk conditions | 41 |
antibody titer | 41 |
older age | 41 |
much higher | 41 |
virus evolution | 41 |
linked sialic | 41 |
chest radiograph | 41 |
gold standard | 41 |
surface proteins | 41 |
three days | 41 |
phylogenetic analyses | 41 |
associated mortality | 41 |
lethal influenza | 41 |
two influenza | 41 |
national health | 41 |
septic shock | 41 |
standard deviation | 41 |
inflammatory responses | 41 |
influenza spread | 41 |
protective effect | 41 |
endothelial cells | 41 |
live poultry | 41 |
reactive antibodies | 41 |
million deaths | 41 |
viral strains | 41 |
antigenic variants | 41 |
global health | 41 |
antigen detection | 41 |
na genes | 41 |
pandemic flu | 40 |
similar results | 40 |
vaccine composition | 40 |
risk individuals | 40 |
human adaptation | 40 |
darby canine | 40 |
pandemic mortality | 40 |
fusion protein | 40 |
like illnesses | 40 |
acid receptors | 40 |
associated pneumonia | 40 |
elderly population | 40 |
experimental infection | 40 |
asian countries | 40 |
day post | 40 |
virus rna | 40 |
influenza diagnostic | 40 |
medical records | 40 |
signaling pathway | 40 |
influenza vaccinations | 40 |
early treatment | 40 |
vaccine design | 40 |
resistance among | 40 |
gestational age | 40 |
poultry workers | 40 |
pneumococcal pneumonia | 40 |
na inhibitors | 40 |
rates among | 40 |
cell epitopes | 40 |
viral pathogens | 40 |
new vaccine | 40 |
may contribute | 40 |
avian species | 40 |
laboratory confirmation | 39 |
avian virus | 39 |
applied biosystems | 39 |
seasonal epidemics | 39 |
different strains | 39 |
small number | 39 |
alveolar epithelial | 39 |
term care | 39 |
influenza symptoms | 39 |
prevent influenza | 39 |
pneumonia caused | 39 |
influenza positive | 39 |
reactive antibody | 39 |
diagnostic testing | 39 |
sample collection | 39 |
underlying conditions | 39 |
low ph | 39 |
statistical analysis | 39 |
higher proportion | 39 |
disease transmission | 39 |
mg ml | 39 |
risk communication | 39 |
antiviral responses | 39 |
animal influenza | 39 |
time points | 39 |
antigenically distinct | 38 |
clinical manifestations | 38 |
virus research | 38 |
sars coronavirus | 38 |
emergency response | 38 |
protective immune | 38 |
viruses among | 38 |
global pandemic | 38 |
meteorological factors | 38 |
influenza control | 38 |
treatment groups | 38 |
significant increase | 38 |
life sciences | 38 |
conformational change | 38 |
findings suggest | 38 |
polymerase complex | 38 |
fatal human | 38 |
body temperature | 38 |
chikungunya virus | 38 |
studies suggest | 38 |
human pandemic | 38 |
review board | 38 |
pandemic vaccines | 38 |
cellular immunity | 38 |
phase iii | 38 |
response efforts | 38 |
long term | 38 |
pandemic wave | 38 |
rna segments | 38 |
hospital stay | 38 |
airborne transmission | 38 |
pneumococcal vaccine | 38 |
rsv disease | 38 |
low pathogenic | 38 |
described previously | 38 |
research institute | 38 |
host responses | 38 |
drug administration | 38 |
disease prevention | 38 |
cancer patients | 37 |
red blood | 37 |
coverage among | 37 |
significantly different | 37 |
immunodeficiency virus | 37 |
stay home | 37 |
hospital mortality | 37 |
first pandemic | 37 |
clinical disease | 37 |
adverse reactions | 37 |
global mortality | 37 |
cytopathic effect | 37 |
virological surveillance | 37 |
virus polymerase | 37 |
infection rates | 37 |
adapted influenza | 37 |
pandemic period | 37 |
joint prevention | 37 |
face mask | 37 |
reassortant viruses | 37 |
nucleic acids | 37 |
influenza treatment | 37 |
person transmission | 37 |
least two | 37 |
south africa | 37 |
increased mortality | 37 |
mainland china | 37 |
positive results | 37 |
rapid diagnostic | 37 |
recombinant ha | 37 |
pandemic avian | 37 |
phase ii | 37 |
pdm viruses | 37 |
vertebrate hosts | 37 |
infected animals | 37 |
arthropod vectors | 37 |
confirmed human | 37 |
laboratory confirmed | 37 |
virus infected | 37 |
health system | 37 |
tract disease | 37 |
mesenchymal stem | 37 |
climate change | 37 |
lung pathology | 36 |
blood samples | 36 |
nasal wash | 36 |
new strain | 36 |
ethics committee | 36 |
higher rates | 36 |
antigenic changes | 36 |
mean temperature | 36 |
subunit vaccine | 36 |
sari cases | 36 |
past decade | 36 |
low levels | 36 |
associated hospitalizations | 36 |
gene therapy | 36 |
secondary infections | 36 |
signaling pathways | 36 |
critical illness | 36 |
one dose | 36 |
virus disease | 36 |
persons aged | 36 |
positive rate | 36 |
current influenza | 36 |
among humans | 36 |
randomized trial | 36 |
laboratory results | 36 |
transport medium | 36 |
school closure | 36 |
vaccination program | 36 |
commonly used | 36 |
sari patients | 36 |
literature review | 36 |
influenza influenza | 36 |
disease caused | 36 |
medicinal plants | 35 |
death rate | 35 |
world war | 35 |
asian influenza | 35 |
classical swine | 35 |
flu season | 35 |
detect influenza | 35 |
phylogenetic trees | 35 |
among health | 35 |
year period | 35 |
ic values | 35 |
vaccination strategies | 35 |
mass gathering | 35 |
reassortant virus | 35 |
significantly associated | 35 |
health interventions | 35 |
ozone exposure | 35 |
nasal washes | 35 |
global spread | 35 |
observational study | 35 |
viral particles | 35 |
recombinant viruses | 35 |
elderly individuals | 35 |
antibody titres | 35 |
personal hygiene | 35 |
adaptive immunity | 35 |
univariate analysis | 35 |
well known | 35 |
previous study | 35 |
high sensitivity | 35 |
functional genomics | 35 |
attenuated vaccines | 35 |
antibiotic treatment | 35 |
positive specimens | 35 |
one year | 35 |
genetic characteristics | 35 |
lessons learned | 35 |
haemophilus influenzae | 35 |
relatively low | 35 |
test results | 35 |
dis doi | 35 |
viral protein | 35 |
health status | 35 |
virus ha | 35 |
patients aged | 35 |
japanese encephalitis | 35 |
rna virus | 35 |
ms patients | 35 |
gastrointestinal symptoms | 35 |
baloxavir marboxil | 35 |
information system | 35 |
post infection | 35 |
ha stalk | 35 |
ha stem | 34 |
trivalent inactivated | 34 |
heterosubtypic immunity | 34 |
victoria lineage | 34 |
diagnostic test | 34 |
acid sequence | 34 |
blood cells | 34 |
care units | 34 |
death rates | 34 |
chronic conditions | 34 |
health services | 34 |
cells infected | 34 |
cytokine production | 34 |
met een | 34 |
molecular basis | 34 |
novel coronavirus | 34 |
crystal structure | 34 |
control mechanism | 34 |
human services | 34 |
single radial | 34 |
organ failure | 34 |
first time | 34 |
exact test | 34 |
influenza ha | 34 |
demographic characteristics | 34 |
data collected | 34 |
genetic variants | 34 |
data analysis | 34 |
nasopharyngeal swab | 34 |
atypical pneumonia | 34 |
respiratory rate | 34 |
year old | 34 |
mg twice | 34 |
human seasonal | 34 |
also known | 34 |
first influenza | 34 |
influenza deaths | 34 |
older children | 34 |
based study | 34 |
human immunodeficiency | 34 |
cell tropism | 33 |
potential conflicts | 33 |
influenza antiviral | 33 |
simplex virus | 33 |
transmission rate | 33 |
respiratory secretions | 33 |
i interferon | 33 |
will help | 33 |
humoral responses | 33 |
last years | 33 |
hemagglutinin gene | 33 |
determine whether | 33 |
influenza types | 33 |
bronchoalveolar lavage | 33 |
type influenza | 33 |
antigenic variation | 33 |
resident memory | 33 |
fast set | 33 |
treating influenza | 33 |
western siberia | 33 |
global burden | 33 |
institutional review | 33 |
cell membrane | 33 |
previously reported | 33 |
virus pathogenesis | 33 |
influenza test | 33 |
influenza complications | 33 |
genetic changes | 33 |
laboratory diagnosis | 33 |
influenza pathogenesis | 33 |
point mutations | 33 |
pilot study | 33 |
neu ac | 33 |
virus nucleoprotein | 33 |
epidemic season | 33 |
genome sequencing | 33 |
fatal case | 33 |
air quality | 33 |
binding properties | 33 |
case definitions | 33 |
days later | 33 |
based surveillance | 33 |
negative control | 32 |
species barrier | 32 |
bacterial coinfections | 32 |
tympanic temperature | 32 |
novel virus | 32 |
suspected cases | 32 |
nucleotide sequence | 32 |
intranasal administration | 32 |
second wave | 32 |
influenza hospitalizations | 32 |
significant morbidity | 32 |
much lower | 32 |
virus production | 32 |
otherwise healthy | 32 |
mass vaccination | 32 |
mucosal immunity | 32 |
although influenza | 32 |
severe iav | 32 |
statin treatment | 32 |
clinical outcome | 32 |
vaccine supply | 32 |
retrospective study | 32 |
nursing homes | 32 |
better understanding | 32 |
broad spectrum | 32 |
astrakhan region | 32 |
highest risk | 32 |
positive cases | 32 |
sensitivity analysis | 32 |
viral vectors | 32 |
one case | 32 |
bacterial co | 32 |
pandemic situation | 32 |
one virus | 32 |
statistical analyses | 32 |
seasonal vaccine | 32 |
influenza sentinel | 32 |
household contacts | 32 |
cell types | 32 |
patients presenting | 32 |
north american | 32 |
immunocompromised individuals | 32 |
pandemic vaccination | 32 |
protective equipment | 32 |
studies using | 32 |
adamantane resistance | 32 |
results show | 31 |
will need | 31 |
molecular characterization | 31 |
two weeks | 31 |
mean age | 31 |
proteolytic cleavage | 31 |
avian origin | 31 |
also reported | 31 |
sars outbreak | 31 |
chicken embryos | 31 |
infected avian | 31 |
adult population | 31 |
relative risk | 31 |
increased susceptibility | 31 |
guinea pigs | 31 |
human host | 31 |
underlying chronic | 31 |
among infants | 31 |
total population | 31 |
higher levels | 31 |
expression changes | 31 |
genetic diversity | 31 |
influenza testing | 31 |
rate among | 31 |
personal protective | 31 |
ticks collected | 31 |
live influenza | 31 |
two viruses | 31 |
viruses using | 31 |
head domain | 31 |
dengue virus | 31 |
virus variants | 31 |
million cases | 31 |
influenza subtype | 31 |
among hospitalized | 31 |
immunization program | 31 |
bird markets | 31 |
cell memory | 31 |
human infected | 31 |
binding preference | 31 |
analysis using | 31 |
cerebrospinal fluid | 31 |
phylogenetic tree | 31 |
positive influenza | 31 |
among pregnant | 31 |
pediatric influenza | 31 |
na subtypes | 31 |
fatty acid | 31 |
humoral immunity | 31 |
active site | 31 |
diseases society | 31 |
different types | 31 |
limited number | 30 |
international catalogue | 30 |
novel avian | 30 |
following vaccination | 30 |
soviet union | 30 |
virus propagation | 30 |
viral membrane | 30 |
supplementary material | 30 |
excess deaths | 30 |
nursing home | 30 |
vaccine hesitancy | 30 |
per day | 30 |
national institutes | 30 |
one patient | 30 |
secondary cases | 30 |
seasonal flu | 30 |
nasal congestion | 30 |
medrxiv preprint | 30 |
clinical diagnosis | 30 |
avian strains | 30 |
also showed | 30 |
corticosteroid treatment | 30 |
health education | 30 |
bij een | 30 |
regression analysis | 30 |
odds ratios | 30 |
cytoplasmic tail | 30 |
ann arbor | 30 |
swine origin | 30 |
pandemic alert | 30 |
single nucleotide | 30 |
hematopoietic stem | 30 |
viruses influenza | 30 |
fatal outcome | 30 |
human coronavirus | 30 |
household members | 30 |
lymph nodes | 30 |
growth factor | 30 |
study also | 30 |
room temperature | 30 |
replication cycle | 30 |
specimen collection | 30 |
surveillance program | 30 |
glycosylation sites | 30 |
life science | 30 |
current vaccines | 30 |
antiviral effects | 30 |
febrile respiratory | 30 |
care providers | 30 |
positive patients | 30 |
viral antigens | 30 |
regression models | 30 |
antigenic sin | 30 |
years ago | 30 |
infections among | 29 |
twentieth century | 29 |
major antigenic | 29 |
like receptors | 29 |
past years | 29 |
environmental factors | 29 |
winter months | 29 |
antiviral medications | 29 |
last year | 29 |
lung lesions | 29 |
weekly number | 29 |
labor market | 29 |
influenza hospitalization | 29 |
airline travel | 29 |
alveolar damage | 29 |
genetic analysis | 29 |
secondary infection | 29 |
modelling study | 29 |
vaccines based | 29 |
lethal challenge | 29 |
hemagglutinin protein | 29 |
antibodies directed | 29 |
inactivated virus | 29 |
may cause | 29 |
study using | 29 |
next generation | 29 |
immunosuppressed patients | 29 |
hi antibody | 29 |
coverage rates | 29 |
respiratory droplets | 29 |
high yield | 29 |
patients treated | 29 |
antigenic site | 29 |
health surveillance | 29 |
renal failure | 29 |
control groups | 29 |
data obtained | 29 |
better understand | 29 |
oxygen saturation | 29 |
tcid ml | 29 |
health professionals | 29 |
nk cells | 29 |
close contacts | 29 |
high rates | 29 |
ha proteins | 29 |
live virus | 29 |
local health | 29 |
individuals aged | 29 |
young infants | 29 |
study found | 29 |
related mortality | 29 |
poultry markets | 29 |
inhibition assay | 29 |
calculated using | 29 |
poor outcome | 29 |
antivirale middelen | 29 |
tijdens een | 29 |
systematic reviews | 29 |
current pandemic | 29 |
healthy young | 28 |
vaccination history | 28 |
activation ph | 28 |
people aged | 28 |
acute otitis | 28 |
primary health | 28 |
new vaccines | 28 |
production capacity | 28 |
inhibits influenza | 28 |
control efforts | 28 |
reporting system | 28 |
high virulence | 28 |
natural killer | 28 |
previously healthy | 28 |
diffuse alveolar | 28 |
crucial role | 28 |
ex vivo | 28 |
natural history | 28 |
military recruits | 28 |
domestic animals | 28 |
russian federation | 28 |
less common | 28 |
specimens collected | 28 |
basic amino | 28 |
inclusion criteria | 28 |
also shown | 28 |
control strategies | 28 |
south america | 28 |
hours post | 28 |
research council | 28 |
primorsky krai | 28 |
viral na | 28 |
internal proteins | 28 |
aged children | 28 |
strongly associated | 28 |
rsv vaccine | 28 |
recombinant protein | 28 |
clinical illness | 28 |
primary human | 28 |
genetic variation | 28 |
sentinel hospitals | 28 |
glycosylation site | 28 |
class i | 28 |
interpandemic influenza | 28 |
like particle | 28 |
based methods | 28 |
mortality risk | 28 |
total rna | 28 |
may explain | 28 |
infected cell | 28 |
bronchial epithelial | 28 |
well plates | 28 |
influenza epidemiology | 28 |
gene segment | 28 |
viruses cause | 28 |
developed countries | 28 |
vaccination campaign | 28 |
associated deaths | 27 |
multiplex pcr | 27 |
guinea pig | 27 |
reactive oxygen | 27 |
posted july | 27 |
pneumonia due | 27 |
large amounts | 27 |
will also | 27 |
york city | 27 |
might also | 27 |
low level | 27 |
infected poultry | 27 |
intravenous peramivir | 27 |
laboratory data | 27 |
anticipated compliance | 27 |
ae lg | 27 |
molecular epidemiology | 27 |
health systems | 27 |
caspian sea | 27 |
infectious dose | 27 |
sari case | 27 |
false negative | 27 |
high viral | 27 |
several years | 27 |
human adenovirus | 27 |
viral mrna | 27 |
treated mice | 27 |
attenuated virus | 27 |
chronic pulmonary | 27 |
human rhinovirus | 27 |
potentially pandemic | 27 |
disease outbreaks | 27 |
herd immunity | 27 |
randomised trial | 27 |
del virus | 27 |
mdck cell | 27 |
urban areas | 27 |
health protection | 27 |
log tcid | 27 |
detection limit | 27 |
epidemiological studies | 27 |
winter season | 27 |
patients may | 27 |
mass spectrometry | 27 |
een influenzapandemie | 27 |
aviaire influenza | 27 |
cause mortality | 27 |
rsv infections | 27 |
gene products | 27 |
ha receptor | 27 |
sectional study | 27 |
seasonal vaccines | 27 |
inhaled zanamivir | 27 |
nasal secretions | 27 |
vaccine manufacturers | 27 |
protein expression | 27 |
serological studies | 27 |
passive immunotherapy | 27 |
transcription factor | 27 |
health personnel | 27 |
yellow fever | 27 |
partial protection | 27 |
first week | 27 |
influenza tests | 27 |
antiviral effect | 27 |
birth outcomes | 27 |
mucosal immune | 27 |
membrane oxygenation | 27 |
time period | 27 |
attenuated vaccine | 27 |
binding domain | 27 |
cynomolgus macaques | 27 |
vaccine based | 26 |
epidemiological surveillance | 26 |
children younger | 26 |
vaccination programs | 26 |
virus pneumonia | 26 |
protective behaviors | 26 |
multiple influenza | 26 |
ha subtypes | 26 |
global public | 26 |
response rate | 26 |
results showed | 26 |
vaccine administration | 26 |
influenza detection | 26 |
novel pandemic | 26 |
nucleotide sequences | 26 |
transmission model | 26 |
membrane protein | 26 |
hai antibody | 26 |
health measures | 26 |
antigenic cartography | 26 |
first two | 26 |
two main | 26 |
infections associated | 26 |
puerto rico | 26 |
viral hemagglutinin | 26 |
challenge studies | 26 |
health workers | 26 |
coverage rate | 26 |
interspecies transmission | 26 |
chronic medical | 26 |
good performance | 26 |
influenza causes | 26 |
based reverse | 26 |
mg day | 26 |
mammalian species | 26 |
sari surveillance | 26 |
vaccination policy | 26 |
factors may | 26 |
extracorporeal membrane | 26 |
volga delta | 26 |
high pathogenicity | 26 |
viral antigen | 26 |
infections caused | 26 |
two years | 26 |
viet nam | 26 |
health literacy | 26 |
i ifns | 26 |
two strains | 26 |
virus surveillance | 26 |
case reports | 26 |
biological properties | 26 |
critical review | 26 |
common respiratory | 26 |
among young | 26 |
broad range | 26 |
infection influenza | 26 |
annual vaccination | 26 |
strain selection | 26 |
tm influenza | 26 |
past pandemics | 26 |
hemagglutinin receptor | 26 |
mouse models | 26 |
large scale | 26 |
negative design | 26 |
mortality data | 26 |
group influenza | 26 |
significant reduction | 26 |
disease associated | 26 |
virus pathogenicity | 26 |
sequence alignment | 26 |
na activity | 26 |
randomly selected | 26 |
antigenic differences | 26 |
reading frame | 26 |
nuclear import | 26 |
respiratory pathogen | 26 |
studies conducted | 26 |
vaccination uptake | 26 |
may increase | 26 |
modified vaccinia | 26 |
deaths worldwide | 26 |
virus clearance | 26 |
time point | 26 |
younger age | 26 |
activated protein | 26 |
next year | 26 |
children hospitalized | 26 |
inflammatory cytokine | 26 |
laboratory tests | 26 |
viral isolates | 26 |
like virus | 26 |
class ii | 26 |
healthy individuals | 26 |
multivariate analysis | 25 |
virus assembly | 25 |
transmission dynamics | 25 |
fold increase | 25 |
human challenge | 25 |
experimental studies | 25 |
epidemiological data | 25 |
previous reports | 25 |
two types | 25 |
evidence suggests | 25 |
second dose | 25 |
virus spread | 25 |
early phase | 25 |
broadly protective | 25 |
one hand | 25 |
electron microscopy | 25 |
early stage | 25 |
elderly adults | 25 |
pandemic year | 25 |
may affect | 25 |
creative commons | 25 |
strain leiv | 25 |
virus induces | 25 |
relatively high | 25 |
subtype influenza | 25 |
structural basis | 25 |
transcription factors | 25 |
pregnant mice | 25 |
annual epidemics | 25 |
cell transplant | 25 |
borne viruses | 25 |
conducted using | 25 |
detection rate | 25 |
sporadic cases | 25 |
new jersey | 25 |
cause severe | 25 |
significantly increased | 25 |
binding affinity | 25 |
pneumococcal disease | 25 |
april th | 25 |
surface antigens | 25 |
oxygen therapy | 25 |
antigenic properties | 25 |
among elderly | 25 |
domestic birds | 25 |
vaccines produced | 25 |
seasonal variation | 25 |
see section | 25 |
virus antigen | 25 |
insect cell | 25 |
recombinant hemagglutinin | 25 |
basic reproduction | 25 |
infected children | 25 |
severe complications | 25 |
influenza drugs | 25 |
coping appraisal | 25 |
natural reservoir | 25 |
many years | 25 |
less severe | 25 |
also associated | 25 |
virus receptors | 25 |
proinflammatory cytokine | 25 |
antibiotic use | 25 |
immunomodulatory agents | 25 |
dependent manner | 25 |
become available | 25 |
oseltamivir carboxylate | 25 |
overall mortality | 25 |
genome sequences | 25 |
tissue tropism | 25 |
duck singapore | 25 |
economic impact | 25 |
decision making | 25 |
ha sequences | 25 |
older individuals | 24 |
mdck pf | 24 |
negative controls | 24 |
recent advances | 24 |
regarding influenza | 24 |
surface glycoprotein | 24 |
influenza risk | 24 |
lung inflammation | 24 |
virus among | 24 |
immune protection | 24 |
human virus | 24 |
nonstructural protein | 24 |
care services | 24 |
received influenza | 24 |
molecular mechanisms | 24 |
three influenza | 24 |
dependent rna | 24 |
mild influenza | 24 |
adenovirus type | 24 |
economic burden | 24 |
reproduction numbers | 24 |
different viruses | 24 |
intravenous zanamivir | 24 |
virus titer | 24 |
five years | 24 |
ligand binding | 24 |
health department | 24 |
serum antibodies | 24 |
categorical variables | 24 |
mammalian host | 24 |
mediated immune | 24 |
nasal discharge | 24 |
severe infection | 24 |
throat swab | 24 |
airborne iav | 24 |
available data | 24 |
studies showed | 24 |
virus containing | 24 |
geometric mean | 24 |
two major | 24 |
severely immunocompromised | 24 |
viral transport | 24 |
vaccination campaigns | 24 |
health response | 24 |
acute viral | 24 |
virus pb | 24 |
hospitalized adults | 24 |
host defense | 24 |
nucleotide polymorphisms | 24 |
fold higher | 24 |
medically attended | 24 |
protect mice | 24 |
will provide | 24 |
health departments | 24 |
central asia | 24 |
susceptibility testing | 24 |
hemisphere influenza | 24 |
structural proteins | 24 |
het virus | 24 |
vaccine may | 24 |
envelope glycoproteins | 24 |
influenza antigen | 24 |
ha glycoprotein | 24 |
seasonal vaccination | 24 |
ill children | 24 |
influenza programme | 24 |
rna segment | 24 |
phase clinical | 24 |
sense rna | 24 |
influenza respiratory | 24 |
large numbers | 24 |
asian flu | 24 |
virus haemagglutinin | 24 |
human parainfluenza | 24 |
laboratoryconfirmed influenza | 24 |
virus receptor | 24 |
adjusted odds | 24 |
resistant strains | 24 |
biomedical research | 24 |
sudden onset | 24 |
sao paulo | 24 |
potential confounders | 24 |
virus particle | 24 |
broadly cross | 24 |
lethal infection | 24 |
predicting influenza | 24 |
illness among | 24 |
inhibitor oseltamivir | 24 |
influenza challenge | 24 |
human receptor | 24 |
high proportion | 24 |
treat influenza | 24 |
proton channel | 24 |
asthma exacerbations | 24 |
care settings | 24 |
complement fixation | 24 |
host species | 24 |
per cent | 24 |
novel vaccine | 24 |
local governments | 24 |
icu patients | 24 |
noninfluenza respiratory | 24 |
continuous variables | 24 |
spatially structured | 23 |
highly virulent | 23 |
negative results | 23 |
oral neuraminidase | 23 |
acquired influenza | 23 |
investigation team | 23 |
standard dose | 23 |
reduced viral | 23 |
healthy volunteers | 23 |
mean score | 23 |
year olds | 23 |
younger adults | 23 |
nasal epithelium | 23 |
future influenza | 23 |
health threat | 23 |
may play | 23 |
fatality rates | 23 |
polyprotein precursor | 23 |
allantoic fluid | 23 |
high dose | 23 |
cohort studies | 23 |
epidemiological characteristics | 23 |
written informed | 23 |
nasal swab | 23 |
immune cell | 23 |
ha molecule | 23 |
us government | 23 |
vaccine will | 23 |
cause disease | 23 |
nasal epithelial | 23 |
cardiovascular diseases | 23 |
clinical use | 23 |
described elsewhere | 23 |
university hospital | 23 |
ae versus | 23 |
reassortment events | 23 |
currently licensed | 23 |
multiorgan failure | 23 |
urgent need | 23 |
will allow | 23 |
small proportion | 23 |
low temperature | 23 |
blood cell | 23 |
new strains | 23 |
swab samples | 23 |
median time | 23 |
individuals infected | 23 |
future pandemic | 23 |
natural influenza | 23 |
deaths per | 23 |
nucleocapsid protein | 23 |
saudi arabia | 23 |
asymptomatic infection | 23 |
pdm influenza | 23 |
one week | 23 |
ivanovsky institute | 23 |
original antigenic | 23 |
snp rs | 23 |
preterm birth | 23 |
related deaths | 23 |
human rights | 23 |
antibiotic therapy | 23 |
neuraminidase activity | 23 |
inactivated whole | 23 |
infections due | 23 |
antiviral response | 23 |
cell index | 23 |
relatively small | 23 |
murine models | 23 |
disease virus | 23 |
diverse influenza | 23 |
ebola virus | 23 |
study demonstrated | 23 |
european union | 23 |
influenza circulation | 23 |
prospective cohort | 23 |
federal government | 23 |
mhc class | 23 |
will continue | 23 |
influenza haemagglutinin | 23 |
first months | 23 |
influenza like | 23 |
early warning | 23 |
low risk | 23 |
years age | 23 |
take place | 23 |
participant data | 23 |
poorly immunogenic | 23 |
antibody levels | 23 |
infected humans | 23 |
birth weight | 23 |
missing data | 23 |
multiple sclerosis | 23 |
serological study | 23 |
health emergencies | 23 |
respiratory droplet | 23 |
cases per | 23 |
human capital | 23 |
universal vaccines | 23 |
study participants | 23 |
target cells | 23 |
equine influenza | 23 |
limited settings | 23 |
seasonal epidemic | 23 |
influenza rapid | 22 |
community acquired | 22 |
van der | 22 |
random effect | 22 |
human immune | 22 |
subjects less | 22 |
inflammatory cells | 22 |
oxygen species | 22 |
antigen test | 22 |
health research | 22 |
lung viral | 22 |
point estimates | 22 |
effective vaccination | 22 |
knockout mice | 22 |
incidence rate | 22 |
antiviral efficacy | 22 |
may suggest | 22 |
nonpharmaceutical interventions | 22 |
response measures | 22 |
mammalian cell | 22 |
whole region | 22 |
zoonotic infections | 22 |
become infected | 22 |
particular interest | 22 |
international health | 22 |
medical center | 22 |
additional file | 22 |
five days | 22 |
mouth disease | 22 |
mild disease | 22 |
ns genes | 22 |
long time | 22 |
export protein | 22 |
binding protein | 22 |
rna replication | 22 |
recombinant baculovirus | 22 |
community transmission | 22 |
active surveillance | 22 |
animal studies | 22 |
low pathogenicity | 22 |
therapeutic efficacy | 22 |
preexisting immunity | 22 |
therapeutic strategies | 22 |
higher rate | 22 |
human strains | 22 |
remains unclear | 22 |
naturally occurring | 22 |
pulmonary viral | 22 |
risk persons | 22 |
antigenic characterization | 22 |
abdominal pain | 22 |
ce serocomplex | 22 |
ixodidae ticks | 22 |
rna synthesis | 22 |
lung tissues | 22 |
pr virus | 22 |
iav densities | 22 |
particularly important | 22 |
versus ae | 22 |
high degree | 22 |
short time | 22 |
analysis based | 22 |
infected human | 22 |
clinically diagnosed | 22 |
resistant pandemic | 22 |
vaccine formulations | 22 |
infected people | 22 |
improved survival | 22 |
effective influenza | 22 |
pdm pandemic | 22 |
viral co | 22 |
analyzed using | 22 |
hospitalized cases | 22 |
moving average | 22 |
analysis showed | 22 |
viral diseases | 22 |
highly variable | 22 |
circulating virus | 22 |
mononuclear cells | 22 |
responses induced | 22 |
viruses including | 22 |
individual participant | 22 |
one strain | 22 |
viral neuraminidase | 22 |
using real | 22 |
poisson regression | 22 |
vaccine containing | 22 |
lymph node | 22 |
single amino | 22 |
two distinct | 22 |
immune function | 22 |
median duration | 22 |
per week | 22 |
emerging infections | 22 |
global surveillance | 22 |
pandemic seasons | 22 |
entry screening | 22 |
two studies | 22 |
wt virus | 22 |
ae ae | 22 |
progeny virus | 22 |
key role | 22 |
acid sequences | 22 |
us centers | 22 |
acute lower | 22 |
transmission rates | 22 |
viral surface | 22 |
fixed effects | 22 |
virus titration | 22 |
three types | 22 |
younger children | 22 |
vrnp complex | 22 |
febrile illness | 22 |
essential role | 21 |
tahyna virus | 21 |
polymerase activity | 21 |
reduced susceptibility | 21 |
three times | 21 |
drug delivery | 21 |
viral nucleoprotein | 21 |
clinical findings | 21 |
vaccine immunogenicity | 21 |
disease progression | 21 |
health organisation | 21 |
fowl plague | 21 |
infected individual | 21 |
cumulative number | 21 |
hematological abnormalities | 21 |
recombinant virus | 21 |
spike protein | 21 |
escape mutants | 21 |
virus ankara | 21 |
neurologic complications | 21 |
study protocol | 21 |
clinical information | 21 |
potential impact | 21 |
viruses detected | 21 |
healthcare system | 21 |
bevs platform | 21 |
hsct recipients | 21 |
coiled coil | 21 |
dendritic cell | 21 |
hospitalization rate | 21 |
several days | 21 |
vaccinated individuals | 21 |
pig model | 21 |
surfactant protein | 21 |
age years | 21 |
vaccine induces | 21 |
pharmaceutical interventions | 21 |
tree length | 21 |
will require | 21 |
high titers | 21 |
protease inhibitor | 21 |
quality control | 21 |
acid change | 21 |
poultry farms | 21 |
influenza antigens | 21 |
care system | 21 |
may reduce | 21 |
tropical regions | 21 |
rapid viral | 21 |
children may | 21 |
simulation model | 21 |
two patients | 21 |
live vaccines | 21 |
effective vaccines | 21 |
publicly available | 21 |
plos one | 21 |
ifn production | 21 |
may require | 21 |
highly sensitive | 21 |
intranasal influenza | 21 |
regulatory factor | 21 |
middle ear | 21 |
hospitalization among | 21 |
first case | 21 |
isolation rate | 21 |
hla alleles | 21 |
high concentrations | 21 |
communicable diseases | 21 |
descriptive study | 21 |
positive control | 21 |
live bird | 21 |
inhibitory effect | 21 |
without pneumonia | 21 |
virus pandemic | 21 |
current vaccine | 21 |
ns proteins | 21 |
antiviral medication | 21 |
clinical study | 21 |
ha head | 21 |
much less | 21 |
associated respiratory | 21 |
clinical benefit | 21 |
combination therapy | 21 |
southeastern asia | 21 |
runny nose | 21 |
genome sequence | 21 |
cellular responses | 21 |
nonhuman primates | 21 |
traditional chinese | 21 |
large outbreak | 21 |
transcriptase polymerase | 21 |
serological evidence | 21 |
general practitioner | 21 |
dose oseltamivir | 21 |
statin use | 21 |
financial support | 21 |
british columbia | 21 |
hand washing | 21 |
wide variety | 21 |
relatively mild | 21 |
time periods | 21 |
mg dl | 21 |
rainy season | 21 |
alere tm | 21 |
escherichia coli | 21 |
east asia | 21 |
major cause | 21 |
virus growth | 21 |
droplet transmission | 21 |
host innate | 21 |
provide protection | 21 |
coronavirus disease | 21 |
syndromic surveillance | 21 |
results indicate | 21 |
seasonal strains | 21 |
pathogenic strains | 21 |
postexposure prophylaxis | 21 |
plasmacytoid dendritic | 21 |
viral etiology | 21 |
among healthcare | 21 |
threat posed | 21 |
plasma cells | 21 |
ae ml | 21 |
annual seasonal | 21 |
probably due | 21 |
vaccine response | 21 |
selection process | 21 |
city model | 20 |
pneumococcal vaccinations | 20 |
conserved influenza | 20 |
vaccination may | 20 |
adapted viruses | 20 |
influenza genome | 20 |
serine proteases | 20 |
medical sciences | 20 |
collected data | 20 |
bacterial suprainfection | 20 |
acute myocardial | 20 |
virus neutralization | 20 |
eastern asia | 20 |
two surface | 20 |
haemorrhagic fever | 20 |
disease influenza | 20 |
vaccines may | 20 |
current status | 20 |
swab specimens | 20 |
vaccine strategies | 20 |
cause respiratory | 20 |
virus protein | 20 |
previous pandemics | 20 |
infection induces | 20 |
new viruses | 20 |
less frequently | 20 |
host immunity | 20 |
readily available | 20 |
acid extraction | 20 |
antibody titre | 20 |
causative agent | 20 |
cell viability | 20 |
haemagglutination inhibition | 20 |
reference laboratory | 20 |
influenza virion | 20 |
recent influenza | 20 |
circulating strain | 20 |
primary infection | 20 |
weekly influenza | 20 |
channel activity | 20 |
type iii | 20 |
virus gene | 20 |
west africa | 20 |
ct values | 20 |
using data | 20 |
people living | 20 |
stem cells | 20 |
membrane proteins | 20 |
species transmission | 20 |
glass opacities | 20 |
complete protection | 20 |
yamagata lineage | 20 |
selection pressure | 20 |
ventilatory support | 20 |
study reported | 20 |
influenza date | 20 |
vaccine studies | 20 |
high prevalence | 20 |
infected person | 20 |
study may | 20 |
czech republic | 20 |
using reverse | 20 |
ng ml | 20 |
lesser extent | 20 |
pandemic season | 20 |
spectrum antiviral | 20 |
wild ducks | 20 |
resistant staphylococcus | 20 |
neutralizing activity | 20 |
flu watch | 20 |
virus outbreak | 20 |
hospitalization rates | 20 |
virus detected | 20 |
set infa | 20 |
cases reported | 20 |
bacterial coinfection | 20 |
increasing number | 20 |
gastrointestinal tract | 20 |
clinically relevant | 20 |
data sources | 20 |
emergency departments | 20 |
sterilizing immunity | 20 |
pandemic caused | 20 |
disease onset | 20 |
cell proliferation | 20 |
specific immune | 20 |
viral glycoproteins | 20 |
took place | 20 |
vaccine administered | 20 |
school children | 20 |
may present | 20 |
ambient pm | 20 |
healthcare providers | 20 |
vaccine trials | 20 |
socioeconomic status | 20 |
mediated protection | 20 |
control animals | 20 |
rna extraction | 20 |
aged months | 20 |
children influenza | 20 |
authors read | 20 |
acid amplification | 20 |
bhanja virus | 20 |
among people | 20 |
multiplex real | 20 |
control practices | 20 |
takes place | 20 |
host adaptation | 20 |
within weeks | 20 |
supportive care | 20 |
linked immunosorbent | 20 |
data sets | 20 |
final manuscript | 20 |
full text | 20 |
chronic illnesses | 20 |
also present | 20 |
polymerase genes | 20 |
biosafety level | 20 |
new technologies | 20 |
matrix gene | 20 |
baculovirus expression | 20 |
economic history | 20 |
people worldwide | 20 |
orthomyxoviridae family | 20 |
protects mice | 20 |
viral fusion | 19 |
solid organ | 19 |
increased morbidity | 19 |
control studies | 19 |
nasopharyngeal aspirates | 19 |
viral components | 19 |
family orthomyxoviridae | 19 |
previous season | 19 |
viral ribonucleoprotein | 19 |
communityacquired pneumonia | 19 |
copy number | 19 |
ethnic groups | 19 |
contact transmission | 19 |
infection caused | 19 |
sustained human | 19 |
previous exposure | 19 |
limited data | 19 |
clinical case | 19 |
seasonal patterns | 19 |
cross protection | 19 |
rna genome | 19 |
enveloped viruses | 19 |
severe human | 19 |
selective pressure | 19 |
dna viruses | 19 |
face masks | 19 |
virus antigens | 19 |
newly synthesized | 19 |
leading cause | 19 |
especially important | 19 |
proteolytic activation | 19 |
hpai virus | 19 |
retrospective cohort | 19 |
will likely | 19 |
vaccine doses | 19 |
patients receiving | 19 |
candidate vaccines | 19 |
airway epithelial | 19 |
many studies | 19 |
subunit influenza | 19 |
glycan microarray | 19 |
camphoric acid | 19 |
influenza isolates | 19 |
laiv candidates | 19 |
develop new | 19 |
scientific community | 19 |
virus taxonomy | 19 |
treatment group | 19 |
small molecule | 19 |
first identified | 19 |
two children | 19 |
virus emerged | 19 |
cell activation | 19 |
health agencies | 19 |
severe clinical | 19 |
novel strain | 19 |
pandemic plans | 19 |
new viral | 19 |
care ethics | 19 |
seasonal human | 19 |
average number | 19 |
viral pathogenesis | 19 |
great depression | 19 |
emerging pandemic | 19 |
outpatient visits | 19 |
pcr methods | 19 |
flu vaccination | 19 |
first human | 19 |
strategic plan | 19 |
unpublished data | 19 |
cost savings | 19 |
generation influenza | 19 |
transmembrane domain | 19 |
assessed using | 19 |
mathematical model | 19 |
close proximity | 19 |
vulnerable populations | 19 |
convalescent plasma | 19 |
human receptors | 19 |
viral genes | 19 |
measured using | 19 |
descriptive statistics | 19 |
seasonal viruses | 19 |
likely due | 19 |
previously published | 19 |
lower mortality | 19 |
sandfly fever | 19 |
first isolated | 19 |
increased influenza | 19 |
school students | 19 |
influenza clinical | 19 |
tested using | 19 |
swine viruses | 19 |
vaccination behaviours | 19 |
spread rapidly | 19 |
hemophagocytic syndrome | 19 |
per hour | 19 |
bovine serum | 19 |
study subjects | 19 |
first century | 19 |
mortality due | 19 |
mild illness | 19 |
airborne influenza | 19 |
virus lineages | 19 |
human subjects | 19 |
consecutive seasons | 19 |
immunity induced | 19 |
eastern mediterranean | 19 |
patient management | 19 |
bacterial superinfection | 19 |
serum igg | 19 |
may represent | 19 |
cell receptors | 19 |
cystic fibrosis | 19 |
kong flu | 19 |
international classification | 19 |
diagnostic accuracy | 19 |
wind speed | 19 |
virus attachment | 19 |
virological characteristics | 19 |
i clinical | 19 |
cough etiquette | 19 |
pandemic scenario | 19 |
million doses | 19 |
acetylneuraminic acid | 19 |
endosomal membrane | 19 |
high morbidity | 19 |
also used | 19 |
comorbid conditions | 19 |
multiple sequence | 19 |
diagnosed influenza | 19 |
emerging viruses | 19 |
open access | 19 |
vaccine use | 19 |
positive predictive | 19 |
pleural effusion | 19 |
international committee | 19 |
meteorological data | 19 |
simultaneous detection | 18 |
influenza immunity | 18 |
ha genes | 18 |
hospital discharge | 18 |
common among | 18 |
population level | 18 |
protease inhibitors | 18 |
viral identification | 18 |
reference laboratories | 18 |
clinical development | 18 |
viral diagnosis | 18 |
lipid bilayer | 18 |
mild symptoms | 18 |
worth noting | 18 |
randomized clinical | 18 |
virus epidemics | 18 |
reported among | 18 |
virus showed | 18 |
nosocomial transmission | 18 |
immunized mice | 18 |
national center | 18 |
human serum | 18 |
envelope glycoprotein | 18 |
associated hospitalization | 18 |
pcr testing | 18 |
nanopore sequencing | 18 |
temperate regions | 18 |
zika virus | 18 |
high temperature | 18 |
van influenza | 18 |
critical role | 18 |
near future | 18 |
common cause | 18 |
acute phase | 18 |
resistant variants | 18 |
population density | 18 |
historical data | 18 |
live births | 18 |
determined using | 18 |
nairovirus genus | 18 |
significant number | 18 |
among older | 18 |
md simulations | 18 |
signal overlap | 18 |
increased incidence | 18 |
highest level | 18 |
acid substitution | 18 |
chinese medicine | 18 |
reported influenza | 18 |
pediatric population | 18 |
human case | 18 |
antigenically related | 18 |
species barriers | 18 |
incidence rates | 18 |
samples tested | 18 |
travel rate | 18 |
pandemic will | 18 |
hiv infection | 18 |
full genome | 18 |
clinical care | 18 |
previous work | 18 |
fluor tm | 18 |
intervention strategies | 18 |
us department | 18 |
cell transplantation | 18 |
antigenic change | 18 |
immunosorbent assay | 18 |
one influenza | 18 |
clinical impact | 18 |
one doi | 18 |
sentinel ducks | 18 |
prior exposure | 18 |
infected birds | 18 |
model selection | 18 |
sporadic human | 18 |
least three | 18 |
vaccine induced | 18 |
third trimester | 18 |
epidemic curve | 18 |
induced apoptosis | 18 |
global seasonal | 18 |
health concern | 18 |
information criterion | 18 |
propensity score | 18 |
important factor | 18 |
genetically modified | 18 |
primary case | 18 |
made available | 18 |
health information | 18 |
iiv immunization | 18 |
human bocavirus | 18 |
clinical effectiveness | 18 |
pf cells | 18 |
infection associated | 18 |
aerosolized ribavirin | 18 |
illness rates | 18 |
cytokine response | 18 |
association rates | 18 |
epidemics occur | 18 |
antibody production | 18 |
vaccine dose | 18 |
prevent infection | 18 |
tissue damage | 18 |
inactivated split | 18 |
states influenza | 18 |
new caledonia | 18 |
reactive protein | 18 |
higher mortality | 18 |
care personnel | 18 |
serocomplex viruses | 18 |
disease outcome | 18 |
among high | 18 |
live vaccine | 18 |
white blood | 18 |
south wales | 18 |
healthcare settings | 18 |
potential role | 18 |
copies ml | 18 |
prolonged viral | 18 |
sputum samples | 18 |
factors affecting | 18 |
australian government | 18 |
risk population | 18 |
segmented genome | 18 |
increasing age | 18 |
efficient human | 18 |
cardiac disease | 18 |
related morbidity | 18 |
using spss | 18 |
health agency | 18 |
southeast asian | 18 |
oseltamivir therapy | 18 |
apical surface | 18 |
contracting influenza | 18 |
viral fitness | 18 |
new south | 18 |
synthetic biology | 18 |
glycan shield | 18 |
vectored vaccines | 18 |
challenge virus | 18 |
binding pocket | 18 |
molecular biology | 18 |
previous influenza | 18 |
serious adverse | 18 |
viral transmission | 18 |
pandemic may | 18 |
virological data | 18 |
primary binding | 18 |
children months | 18 |
cardiovascular events | 18 |
pandemic threats | 18 |
infections may | 18 |
lung lobes | 18 |
monovalent vaccine | 18 |
associated complications | 18 |
kg cr | 18 |
human sera | 18 |
different species | 18 |
influenza period | 18 |
risk populations | 18 |
economic losses | 18 |
acute hospitalization | 18 |
interferon response | 18 |
analysis revealed | 18 |
clinical picture | 18 |
research agenda | 18 |
viral interference | 18 |
new antiviral | 18 |
fatty acids | 18 |
signal peptide | 18 |
may still | 18 |